BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: Potential therapeutic targets

Eric S. Calhoun, Jessa B. Jones, Raheela Ashfaq, Volkan Adsay, Suzanne J. Baker, Virginia Valentine, Paula M. Hempen, Werner Hilgers, Charles J. Yeo, Ralph H Hruban, Scott E Kern

Research output: Contribution to journalArticle

Abstract

The recognition of biologically distinct tumor subsets is fundamental to understanding tumorigenesis. This study investigated the mutational status of the serine/threonine kinase BRAF and the cyclin E regulator FBXW7 (CDC4, FBW7, AGO, SEL10) related to two distinct pancreatic carcinoma subsets: the medullary KRAS2-wild-type and the cyclin E overexpressing tumors, respectively. Among KRAS2-wild-type carcinomas, 33% (3 of 9) contained BRAF V599E mutations; one of which was identified in the pancreatic cancer cell line COLO357. Among 74 KRAS2-mutant carcinomas, no BRAF mutations were identified. Among the KRAS2/ BRAF wild-type carcinomas, no mutations within pathway members MEK1, MEK2, ERK1, ERK2, RAP1B, or BAD were found. Using pancreatic cancer microarrays and immunohistochemistry, we determined that 6% (4 of 46 and 5 of 100 in two independent panels) of pancreatic adenocarcinomas overexpress cyclin E. We identified two potential mechanisms for this overexpression including the amplification/gain of CCNE1 gene copies in the Panc-1 and Su86.86 cell lines and a novel somatic homozygous mutation (H460R, in one of 11 pancreatic cancer xenografts having allelic loss) in FBXW7, which was accompanied by cyclin E overexpression by immunohistochemistry. Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.

Original languageEnglish (US)
Pages (from-to)1255-1260
Number of pages6
JournalAmerican Journal of Pathology
Volume163
Issue number4
StatePublished - Oct 1 2003

Fingerprint

Cyclin E
Pancreatic Neoplasms
Mutation
Carcinoma
Adenocarcinoma
Phosphotransferases
Immunohistochemistry
Therapeutics
Cell Line
Loss of Heterozygosity
Protein-Serine-Threonine Kinases
Heterografts
Neoplasms
Carcinogenesis
Genes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Calhoun, E. S., Jones, J. B., Ashfaq, R., Adsay, V., Baker, S. J., Valentine, V., ... Kern, S. E. (2003). BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: Potential therapeutic targets. American Journal of Pathology, 163(4), 1255-1260.

BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer : Potential therapeutic targets. / Calhoun, Eric S.; Jones, Jessa B.; Ashfaq, Raheela; Adsay, Volkan; Baker, Suzanne J.; Valentine, Virginia; Hempen, Paula M.; Hilgers, Werner; Yeo, Charles J.; Hruban, Ralph H; Kern, Scott E.

In: American Journal of Pathology, Vol. 163, No. 4, 01.10.2003, p. 1255-1260.

Research output: Contribution to journalArticle

Calhoun, ES, Jones, JB, Ashfaq, R, Adsay, V, Baker, SJ, Valentine, V, Hempen, PM, Hilgers, W, Yeo, CJ, Hruban, RH & Kern, SE 2003, 'BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: Potential therapeutic targets', American Journal of Pathology, vol. 163, no. 4, pp. 1255-1260.
Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: Potential therapeutic targets. American Journal of Pathology. 2003 Oct 1;163(4):1255-1260.
Calhoun, Eric S. ; Jones, Jessa B. ; Ashfaq, Raheela ; Adsay, Volkan ; Baker, Suzanne J. ; Valentine, Virginia ; Hempen, Paula M. ; Hilgers, Werner ; Yeo, Charles J. ; Hruban, Ralph H ; Kern, Scott E. / BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer : Potential therapeutic targets. In: American Journal of Pathology. 2003 ; Vol. 163, No. 4. pp. 1255-1260.
@article{7019e235f7f143e395c10ad856a4ca2a,
title = "BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: Potential therapeutic targets",
abstract = "The recognition of biologically distinct tumor subsets is fundamental to understanding tumorigenesis. This study investigated the mutational status of the serine/threonine kinase BRAF and the cyclin E regulator FBXW7 (CDC4, FBW7, AGO, SEL10) related to two distinct pancreatic carcinoma subsets: the medullary KRAS2-wild-type and the cyclin E overexpressing tumors, respectively. Among KRAS2-wild-type carcinomas, 33{\%} (3 of 9) contained BRAF V599E mutations; one of which was identified in the pancreatic cancer cell line COLO357. Among 74 KRAS2-mutant carcinomas, no BRAF mutations were identified. Among the KRAS2/ BRAF wild-type carcinomas, no mutations within pathway members MEK1, MEK2, ERK1, ERK2, RAP1B, or BAD were found. Using pancreatic cancer microarrays and immunohistochemistry, we determined that 6{\%} (4 of 46 and 5 of 100 in two independent panels) of pancreatic adenocarcinomas overexpress cyclin E. We identified two potential mechanisms for this overexpression including the amplification/gain of CCNE1 gene copies in the Panc-1 and Su86.86 cell lines and a novel somatic homozygous mutation (H460R, in one of 11 pancreatic cancer xenografts having allelic loss) in FBXW7, which was accompanied by cyclin E overexpression by immunohistochemistry. Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.",
author = "Calhoun, {Eric S.} and Jones, {Jessa B.} and Raheela Ashfaq and Volkan Adsay and Baker, {Suzanne J.} and Virginia Valentine and Hempen, {Paula M.} and Werner Hilgers and Yeo, {Charles J.} and Hruban, {Ralph H} and Kern, {Scott E}",
year = "2003",
month = "10",
day = "1",
language = "English (US)",
volume = "163",
pages = "1255--1260",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer

T2 - Potential therapeutic targets

AU - Calhoun, Eric S.

AU - Jones, Jessa B.

AU - Ashfaq, Raheela

AU - Adsay, Volkan

AU - Baker, Suzanne J.

AU - Valentine, Virginia

AU - Hempen, Paula M.

AU - Hilgers, Werner

AU - Yeo, Charles J.

AU - Hruban, Ralph H

AU - Kern, Scott E

PY - 2003/10/1

Y1 - 2003/10/1

N2 - The recognition of biologically distinct tumor subsets is fundamental to understanding tumorigenesis. This study investigated the mutational status of the serine/threonine kinase BRAF and the cyclin E regulator FBXW7 (CDC4, FBW7, AGO, SEL10) related to two distinct pancreatic carcinoma subsets: the medullary KRAS2-wild-type and the cyclin E overexpressing tumors, respectively. Among KRAS2-wild-type carcinomas, 33% (3 of 9) contained BRAF V599E mutations; one of which was identified in the pancreatic cancer cell line COLO357. Among 74 KRAS2-mutant carcinomas, no BRAF mutations were identified. Among the KRAS2/ BRAF wild-type carcinomas, no mutations within pathway members MEK1, MEK2, ERK1, ERK2, RAP1B, or BAD were found. Using pancreatic cancer microarrays and immunohistochemistry, we determined that 6% (4 of 46 and 5 of 100 in two independent panels) of pancreatic adenocarcinomas overexpress cyclin E. We identified two potential mechanisms for this overexpression including the amplification/gain of CCNE1 gene copies in the Panc-1 and Su86.86 cell lines and a novel somatic homozygous mutation (H460R, in one of 11 pancreatic cancer xenografts having allelic loss) in FBXW7, which was accompanied by cyclin E overexpression by immunohistochemistry. Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.

AB - The recognition of biologically distinct tumor subsets is fundamental to understanding tumorigenesis. This study investigated the mutational status of the serine/threonine kinase BRAF and the cyclin E regulator FBXW7 (CDC4, FBW7, AGO, SEL10) related to two distinct pancreatic carcinoma subsets: the medullary KRAS2-wild-type and the cyclin E overexpressing tumors, respectively. Among KRAS2-wild-type carcinomas, 33% (3 of 9) contained BRAF V599E mutations; one of which was identified in the pancreatic cancer cell line COLO357. Among 74 KRAS2-mutant carcinomas, no BRAF mutations were identified. Among the KRAS2/ BRAF wild-type carcinomas, no mutations within pathway members MEK1, MEK2, ERK1, ERK2, RAP1B, or BAD were found. Using pancreatic cancer microarrays and immunohistochemistry, we determined that 6% (4 of 46 and 5 of 100 in two independent panels) of pancreatic adenocarcinomas overexpress cyclin E. We identified two potential mechanisms for this overexpression including the amplification/gain of CCNE1 gene copies in the Panc-1 and Su86.86 cell lines and a novel somatic homozygous mutation (H460R, in one of 11 pancreatic cancer xenografts having allelic loss) in FBXW7, which was accompanied by cyclin E overexpression by immunohistochemistry. Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend the potential options for therapeutic targeting of kinases in the treatment of phenotypically distinct pancreatic adenocarcinoma subsets.

UR - http://www.scopus.com/inward/record.url?scp=0141425732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141425732&partnerID=8YFLogxK

M3 - Article

C2 - 14507635

AN - SCOPUS:0141425732

VL - 163

SP - 1255

EP - 1260

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 4

ER -